Table 3 Framework for describing enablers and barriers to reclassification emerging from the interviews

• Process and Committee

 ◦ Scientific advisory meeting

 ◦ Application

 ◦ Need for evidence

 ◦ BfArM evaluation

 ◦ Committee membership

 ◦ Committee meeting

 ◦ Committee trust in consumers, pharmacists and companies

 ◦ Conditions or guidelines for supply

 ◦ Attendance at the meeting by an expert for the company

 ◦ Post-committee process

• The Health System including Funding

 ◦ Health funding

 ◦ Access to health care

 ◦ Medical influence and perspectives

 ◦ Pharmacy influence and perspectives

• Industry aspects

• Other factors

 ◦ Consumer culture and behaviour

 ◦ Politics